Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Start of new week recap

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Mar 25, 2024 6:51pm

84 Views

Post# 35951779

RE:RE:RE:RE:RE:Start of new week recap

Hydroqc,

That's exactly what ONC wants you to think.

It's very likely just another tactic to generate interest and feed demand for the ATM.

Kudos to ONC for keeping the pump and dump scheme rolling.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle